Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EJ Janus-associated kinase (JAK) inhibitors
L01EJ03 Pacritinib
D11768 Pacritinib (USAN/INN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Pacritinib
D11768 Pacritinib (USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
D11768 Pacritinib
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
D11768 Pacritinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D11768 Pacritinib
Drug classes [BR:br08332]
Immunological agent
DG02020 JAK inhibitor
D11768 Pacritinib
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D11768 Pacritinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
FLT3 (CD135)
D11768 Pacritinib (USAN/INN) <US>
Non-receptor tyrosine kinases
JAK family
JAK2
D11768 Pacritinib (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11768
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11768
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11768